PET brain scan study for people with terminal illness
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This Phase 3 study tests an amyloid/tau PET brain imaging agent (called [18F]PI-2620). It aims to see how well the scan helps with brain pathology findings in people who are expected to have a life expectancy of 1 year or less.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older
- A doctor expects your life expectancy to be 1 year or less (terminal illness)
- You (or your legally authorized representative) can sign consent, including permission for brain donation
- You can physically tolerate lying still in the PET scanner
- You are not currently receiving certain aggressive life-sustaining treatments (for example, chemotherapy)
- No brain structural problem that would block the PET scan or brain tissue reading
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
This study uses PET/CT/MRI imaging to look for brain “imaging biomarkers” in people across the Alzheimer’s disease range. It may help researchers better understand how Alzheimer’s changes the brain over time and improve future treatments.
This study uses a special brain scan to measure “tau” buildup in people with an inherited form of Alzheimer’s. It may help researchers better understand disease changes and evaluate whether the scan can track them over time.
This study tests a PET scan “tracer” medicine called [18F]MK-6240 to see how tau protein changes show up in the brain. It may help researchers measure disease-related brain changes in people with normal thinking or mild dementia.
This study uses brain imaging to understand changes in the brain during normal aging and early Alzheimer’s disease (AD). It may help researchers spot early brain changes and evaluate how well imaging measures those changes.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.